Ganesh Bheemanaboina¹, Joya Rani Deverashetty² and Srilatha Bashetti³*

¹Tutor, Department of Biochemistry, Dr. PatnamMahender Reddy Institute of Medical Sciences, Chevella, Telangana, India
²Professor and Dean, Department of Physiology, Dr. PatnamMahender Reddy Institute of Medical Sciences, Chevella, Telangana, India
³Associate Professor, Department of Biochemistry, Dr. PatnamMahender Reddy Institute of Medical Sciences, Chevella, Telangana, India

*Corresponding Author: Srilatha Bashetti, Associate Professor, Department of Biochemistry, Dr. PatnamMahender Reddy Institute of Medical Sciences, Chevella, Telangana, India.

Received: March 23, 2023; Published: April 11, 2023

Abstract

Cardiovascular disease (CVD) is one the leading causes of mortality and morbidity in the world. High density lipoproteins (HDL) cholesterol is considered as good cholesterol, as it is inversely associated with the atherosclerotic cardiovascular disease (ASCVD) through the reverse transport cholesterol system. Lifestyle modifications, novel therapeutic and pharmacological therapy towards raising the levels of HDL-C is still under trials. The short review had explained the positive role of high HDL-C in CVD and non CVD cases, but would also like to emphasize the negative effects of high HDL-C. Many guideline state the prominent role of HDL-C in preventing and reducing the risks of CVD but it is suggestive that one should not assume that high levels of HDL-C is a good prognosis instead clinicians should caution the patients with extremely high HDL-C levels and should be evaluated with at-most care by reducing the possibility of other possible associated risk factors. The present review also shortly highlighted the role of HDL-C levels in various non-cardiovascular diseases helping to understand their pathogenesis. The review states that both diet and drugs can increase the levels of HDL-C but could not support that extremely high HDL would prevent CVD and related mortality. HDL-C is good cholesterol within the limits. Further innovative research studies are recommended to establish the exact cut-off ranges of HDL-C levels based upon the cultures, weather and eating habits of the human population across the world.

Keywords: High Density; Lipoprotein; Cholesterol; HDL-C

References

1. Luna-Castillo KP., et al. “Functional Food an Bioactive Compounds on the Modulation of the Functionality of HDL-C: A Narrative Review”. Nutrients 13 (2021): 1165.
2. Franczyk B., et al. “Is a High HDL-Cholesterol Level Always Beneficial?” Biomedicines 9 (2021): 1083.
3. M John Chapman., et al. “Niacin and fibrates in atherogenicdyslipidemia: Pharmacotherapy to reduce cardiovascular risk”. Pharmacology and Therapeutics3 (2010): 314-345.
4. Philip Barter. “The role of HDL-Cholesterol in preventing atherosclerotic disease”. European Heart Journal Supplements (2005): F4-F8.
5. Parhofer KG. “Interaction between glucose and lipid metabolism: more than diabetic dyslipidemia”. Diabetes and Metabolism Journal 5 (2015): 353-362.
6. Taskinen MR and Boren J. “New insights into the pathophysiology of dyslipidemia in type 2 diabetes”. Atherosclerosis 2 (2015): 483-495.
7. Eckel RH., et al. “2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines”. Circulation 25-2 (2013): S76-S99.
8. Adams V., et al. “Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties”. Circulation Research 12 (2013): 1345-1355.
9. Cai M and Zou Z. “Effect of aerobic exercise on blood lipid and glucose in obese or overweight adults: a meta-analysis of randomised controlled trials”. Obesity Research and Clinical Practice 5 (2016): 589-602.
10. Ghafouri K., et al. “Moderate exercise increases affinity of large very low-density lipoproteins for hydrolysis by lipoprotein lipase”. The Journal of Clinical Endocrinology and Metabolism 6 (2015): 2205-2213.
11. Briel M., et al. “Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis”. BMJ 338 (2009): b92.
12. Soran H., et al. “Evidence-based goals in LDL-C reduction”. Clinical Research in Cardiology (2017).
13. Laufs U., et al. “Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk”. Clinical Research in Cardiology Official Journal of the German Cardiac Society 9 (2016): 783-790.
14. Keech A., et al. “Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial”. Lancet9500 (2005): 1849-1861.
15. Ginsberg HN., et al. “Effects of combination lipid therapy in type 2 diabetes mellitus”. The New England Journal of Medicine 17 (2010): 1563-1574.
16. Lavigne PM and Karas RH. “The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression”. Journal of the American College of Cardiology 4 (2013): 440-446.
17. EA Brinton. “Effects of ethanol intake on lipoproteins”. Current Atherosclerotic Reports2 (2012): 108-114.
18. JM Miranda., et al. “Egg and egg-derivative foods: effects on human health and use as functional foods”. Nutrients1 (2015): 706-729.
19. CJ Andersen., et al. “Egg consumption modulates HDL lipid composition and increases the cholesterol- accepting capacity of serum in metabolic syndrome”. Lipids6 (2013): 557-567.
20. PM Moriarty., et al. “Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study”. Journal of Clinical Lipidology6 (2014): 568-575.
21. CY Lee., et al. “Relationship between adiponectin and leptin, and blood lipids in hyperlipidemia patients treated with red yeast rice”. ForschendeKomplementarmedizin 3 (2013): 197-203.
22. SC Halbert., et al. “Tolerability of red yeast rice (2,400 mg twice daily) versus Pravastatin (20 mg twice daily) in patients with previous statin intolerance”. American Journal of Cardiology 2 (2010): 198-204.
23. DJ Becker., et al. “Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial”. Annals of Internal Medicine12 (2009): 830-839.
24. C Stefanutti., et al. “Combined treatment with Dif1stat and diet reduce plasma lipid indicators of moderate hypercholesterolemia more effectively than diet alone: a randomized trial in parallel groups”. Lipids12 (2009): 1141-1148.
25. D Heber., et al. “Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement”. American Journal of Clinical Nutrition2 (1999): 231-236.
26. Z Lu., et al. “Effect of xuezhikang, an extract from red yeast chinese rice, on coronary events in a chinese population with previous myocardial infarction”. American Journal of Cardiology12 (2008): 1689-1693.
27. M Gonzalez-Santiago., et al. “One-month administration of hydroxytyrosol, a phenolic antioxidant present in olive oil, to hyperlipemic rabbits improves blood lipid profile, antioxidant status and reduces atherosclerosis development”. Atherosclerosis1 (2006): 35-42.
28. Fki Z Sahnoun and S Sayadi. “Hypocholesterolemic effects of phenolic extracts and purified hydroxytyrosol recovered from olive mill wastewater in rats fed a cholesterol-rich diet”. Journal of Agricultural and Food Chemistry3 (2007): 624-631.
29. H Jemai., et al. “Phenolic composition, sugar contents and antioxidant activity of Tunisian sweet olive cultivar with regard to fruit ripening”. Journal of Agricultural and Food Chemistry7 (2009): 2961-2968.
30. Hern ´ aez., et al. “Olive ` oil polyphenols enhance high-density lipoprotein function in humans: a randomized controlled trial”. Arteriosclerosis, Thrombosis, and Vascular Biology9 (2014): 2115-2119.
31. MI Covas., et al. “The effect ¨ of polyphenols in olive oil on heart disease risk factors: A randomized trial”. Annals of Internal Medicine5 (2006): 333-341.
32. V Mollace., et al. “Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies”. Fitoterapia 3 (2011): 309-316.
33. M Rondanelli., et al. “Metabolic management in overweight subjects with naive impaired fasting glycaemia by means of a highly standardized extract from cynarascolymus: a double-blind, placebo-controlled, randomized clinical trial”. Phytotherapy Research1 (2014): 33-41.
34. R Bundy., et al. “Artichoke leaf extract (Cynarascolymus) reduces plasma cholesterol in otherwise healthy hypercholesterolemic adults: a randomized, double blind placebocontrolled trial”. Phytomedicine 9 (2008): 668-675.
35. W Englisch., et al. “Efficacy of artichoke dry extract in patients with hyperlipoproteinemia”. Arzneimittel-Forschung/Drug Research 3 (2000): 260-265.
36. JE Brown and CA Rice-Evans. “Luteolin-rich artichoke extract protects low density lipoprotein from oxidation in vitro”. Free Radical Research3 (1998): 247-255.
37. R Gebhardt. “Inhibition of cholesterol biosynthesis in HepG2 cells by artichoke extracts is reinforced by glucosidase retreatment”. Phytotherapy Research4 (2002): 368-372.
38. B Wider., et al. “Artichoke leaf extract for treating hypercholesterolaemia”. Cochrane Database of Systematic Reviews (2009): 4.
39. Madsen CM., et al. “U-shaped relationship of HDL and risk of infectious disease: two prospective population-based cohort studies”. European Heart Journal 39 (2018): 1181-1190.
40. Pedersen KM., et al. “Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals”. Journal of Hematology and Oncology 13 (2020): 129.
41. Liu HM., et al. “Causal effects of genetically predicted cardiovascular risk factors on chronic kidney disease: a two-sample mendelian randomization study”. Frontiers in Genetics 10 (2019): 415.
42. Genga KR., et al. “CETP genetic variant rs1800777 (allele A) is associated with abnormally low HDL-C levels and increased risk of AKI during sepsis”. Scientific Reports 8 (2018): 16764.
43. Wilkins JT., et al. “Coronary heart disease risks associated with high levels of HDL cholesterol”. Journal of the American Heart Association 3 (2014): e000519.
44. Hirata A., et al. “NIPPON DATA90 Research Group. The relationship between very high levels of serum high-density lipoprotein cholesterol and cause-specific mortality in a 20-year follow-up study of Japanese general population”. Journal of Atherosclerosis and Thrombosis 23 (2016): 800-809.
45. Bowe B., et al. “High Density lipoprotein cholesterol and the risk of all-cause mortality among U.S. veterans”. Clinical Journal of the American Society of Nephrology 11 (2016): 1784-1793.
46. Ko DT., et al. “High-density lipoprotein cholesterol and cause-specific mortality in individuals without previous cardiovascular conditions: the CANHEART study”. Journal of the American College of Cardiology 68 (2016): 2073-2083.
47. Madsen CM., et al. “Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies”. European Heart Journal 38 (2017): 2478-2486.
48. Hamer M., et al. “High-density lipoprotein cholesterol and mortality: too much of a good thing?” Arteriosclerosis, Thrombosis, and Vascular Biology 38 (2018): 669-672.
49. Hirata A., et al. “Evidence for Cardiovascular Prevention from Observational Cohorts in Japan (EPOCH-JAPAN) Research Group. Association of extremely high levels of high-density lipoprotein cholesterol with cardiovascular mortality in a pooled analysis of 9 cohort studies including 43,407 individuals: the EPOCH-JAPAN study”. Journal of Clinical Lipidology 12 (2018): 674-684.e5.
50. Mazidi M., et al. “Associations between risk of overall mortality, cause-specific mortality and level of inflammatory factors with extremely low and high high-density lipoprotein cholesterol levels among American adults”. International Journal of Cardiology 276 (2019): 242-247.
51. Oh IH., et al. “Very high high-density lipoprotein cholesterol is associated with increased all-cause mortality in South Koreans”. Atherosclerosis 283 (2019): 43-51.
52. Li ZH., et al. “High-density lipoprotein cholesterol and all-cause and cause-specific mortality among the elderly”. The Journal of Clinical Endocrinology and Metabolism 104 (2019): 3370-3378.
53. Kobayashi D., et al. “Repeated measures of extremely high levels of high-density lipoprotein cholesterol and subsequent all-cause mortality and cardiovascular events: a longitudinal study”. Atherosclerosis 288 (2019): 17-25.
54. Madsen CM., et al. “U-shaped relationship of HDL and risk of infectious disease: two prospective population-based cohort studies”. European Heart Journal 39 (2018): 1181-1190.
55. Pedersen KM., et al. “Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals”. Journal of Hematology and Oncology 13 (2020): 129.
56. Fountoulakis N., et al. “The P274S mutation of lecithin-cholesterol acyltransferase (LCAT) and its clinical manifestations in a large kindred”. American Journal of Kidney Diseases 74 (2019): 510-522.
57. H Jemai., et al. “Lipid-lowering and antioxidant effects of hydroxytyrosol and its triacetylated derivative recovered from olive tree leaves in cholesterol-fed rats”. Journal of Agricultural and Food Chemistry8 (2008): 2630-2636.
58. Genga KR., et al. “CETP genetic variant rs1800777 (allele A) is associated with abnormally low HDL-C levels and increased risk of AKI during sepsis”. Scientific Reports 8 (2018): 16764.
59. Dron JS., et al. “Polygenic determinants in extremes of high-density lipoprotein cholesterol”. Journal of Lipid Research 58 (2017): 2162-2170.
60. Barter PJ and Rye KA. “HDL cholesterol concentration or HDL function: which matters?” European Heart Journal 38 (2017): 2487-2489.
61. Madsen CM and Nordestgaard BG. “Is it time for new thinking about high density lipoprotein?” Arteriosclerosis, Thrombosis, and Vascular Biology 38 (2018): 484-486.
62. Nordestgaard BG., et al. “Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media”. Arteriosclerosis, Thrombosis, and Vascular Biology 15 (1995): 534-542.
63.  

Citation

Citation: Srilatha Bashetti.,et al “The Facts About High Density Lipoprotein Cholesterol (HDL-C). I'm Pretty Good Within Limits".Acta Scientific Nutritional Health 7.5 (2023): 38-44.

Copyright

Copyright: © 2023 Srilatha Bashetti., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.